University of Virginia, Department of Surgery and University of Virginia Cancer Center, PO Box 800709, Charlottesville, VA, USA.
University of Virginia, Department of Surgery and University of Virginia Cancer Center, PO Box 800709, Charlottesville, VA, USA.
Curr Opin Immunol. 2017 Aug;47:85-92. doi: 10.1016/j.coi.2017.07.004. Epub 2017 Jul 26.
There are compelling arguments for designing cancer vaccines specifically to induce CD4 helper T cell responses. Recent studies highlight the crucial role of proliferating, activated effector memory Th1 CD4 T cells in effective antitumor immunity and reveal that CD4 T cells induce more durable immune-mediated tumor control than CD8 T cells. CD4 T cells promote antitumor immunity by numerous mechanisms including enhancing antigen presentation, co-stimulation, T cell homing, T cell activation, and effector function. These effects are mediated at sites of T cell priming and at the tumor microenvironment. Several cancer vaccine approaches induce durable CD4 T cell responses and have promising clinical activity. Future work should further optimize vaccine adjuvants and combination therapies incorporating helper peptide vaccines.
有充分的理由设计专门诱导 CD4 辅助 T 细胞反应的癌症疫苗。最近的研究强调了增殖、激活的效应记忆 Th1 CD4 T 细胞在有效抗肿瘤免疫中的关键作用，并揭示 CD4 T 细胞诱导的免疫介导的肿瘤控制比 CD8 T 细胞更持久。CD4 T 细胞通过多种机制促进抗肿瘤免疫，包括增强抗原呈递、共刺激、T 细胞归巢、T 细胞激活和效应功能。这些作用在 T 细胞启动部位和肿瘤微环境中发挥作用。几种癌症疫苗方法可诱导持久的 CD4 T 细胞反应，并具有有前途的临床活性。未来的工作应进一步优化疫苗佐剂和包含辅助肽疫苗的联合治疗。
